HIV

HIV

Monash Infectious Diseases participates in research studies and clinical trials of new agents for the management of HIV infection.

Investigators and Collaborators

Investigators

HIV Research Coordinator

  • Ms Jess Costa

HIV Specialist Nurses

  • Ms Katie Costello
  • Ms Nina Pannu

Collaborators

Research Studies

Current studies

Australian HIV Observational Database (AHOD)

The Australian HIV Observational Database (AHOD) is an observational cohort study of more than 4,000 HIV positive patients in Australia under routine clinical care. Approximately 30 HIV clinics throughout Australia and New Zealand participate in AHOD. AHOD data are aggregated by researchers at the Kirby Institute on behalf of collaborating sites.

AHOD has described the changing spectrum of causes of death, and patterns of long term immunological and virological response among treated HIV-positive patients. Over the past 15 years, AHOD has demonstrated incremental improvements in virological response for patients initiated on combination ART. Most deaths are now non-AIDS related, and data from AHOD has underscored the fact that if CD4+ counts are at a high level, life expectancy approaches that of the general population.

Project Supporters

  • The Foundation for AIDS Research (amfAR)
  • Unconditional grants from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme and ViiV Healthcare.

AHOD Publications

Melbourne HIV Cohort Study

Objectives

  1. Establish and follow a cohort of 100 HIV treatment naïve patients with 100 HIV negative controls, in order perform and facilitate a wide range of high quality research projects of relevance to people living with HIV.
  2. To create a partnership and infrastructure that encourages high quality collaborative HIV basic, clinical and behavioural science research.

Factors associated with the failure of antiretroviral therapy in HIV-infected adults (PAART)

Primary study objectives

To identify patient, treatment, and socio-economic characteristics predicting antiretroviral therapy (ART) failure over 24 months in HIV-infected patients receiving stable ART.

Australian Positive & Peers Longevity Evaluation Study (APPLES)

Primary study objectives

A comparison of HIV positive (HIV+) and HIV negative (HIV-) participants for a number of key demographic characteristics at baseline. Specifically to perform a cross-sectional analysis of surrogate markers of age related comorbidities, including:

  • Rates of dyslipidemia, hypertension, smoking, vitamin D deficiency
  • Elevated levels of biomarkers of inflammation such as D-dimer, hsCRP, cystatin C, and IL-6.
  • Further, to estimate and compare the 5 and 10 year predicted risk of CVD and bone disease (osteoporosis and hip fracture) using conventional risk calculators such as the Framingham and FRAX scores
  • Assess feasibility of conducting a large ongoing cohort study

HIV Immunity and Cancer Biobanking Study (HI-C)

Primary objective

Establish a prospectively characterised clinical cohort and biorepository of patients with HIV and malignancy, to serve as the basis for clinical and translational studies in oncogenesis and HIV pathogenesis.

Completed studies

HealthMap

HealthMap is a model of care for people with HIV (PWHIV) that includes use of an interactive shared health record and self-management support. The aims of the HealthMap trial are to evaluate engagement of people with HIV (PWHIV) and healthcare providers with the model, and its effectiveness for reducing coronary heart disease risk, enhancing self-management, and improving mental health and quality of life of PWHIV. The study is a two-arm cluster randomised trial involving HIV clinical sites in several states in Australia.

ClinicalTrials.gov Identifier: NCT02178930

HealthMap Publications

Clinical Trials

Current trials

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults (Gilead 1490)

ClinicalTrials.gov Identifier: NCT02607956

Summary

This Phase 3 study will evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + a FDC containing emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, antiretroviral treatment-naive adults at Week 48.

ADVICE: Attenuation of D-dimer using Vorapaxar to target Inflammatory and Coagulation Endpoints

ClinicalTrials.gov Identifier: NCT02394730

Summary

ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer expression and markers of cellular immune activation over a period of 12 weeks among people with HIV infection who are successfully treated with combination antiretroviral therapy containing an HIV integrase inhibitor. A secondary objective of the study will be to demonstrate that following cessation of vorapaxar in patients with well controlled HIV replication there will be an increase in the levels of d-dimer over a 6 week period. 60 participants from 4 clinical sites in Australia and the USA will be recruited and followed for a minimum of 18 weeks.

Completed trials

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

ClinicalTrials.gov Identifier: NCT01471574

Maraviroc Switch Collaborative Study (MARCH)

ClinicalTrials.gov Identifier: NCT01384682

Maraviroc Switch (MARCH) Study Group Publications

A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine (STEAL)

ClinicalTrials.gov Identifier: NCT00192634

STEAL Study Group Publications

Publications

Chronic kidney disease in Australian HIV-infected patients: analysis of the Australian HIV Observational Database.
Cheung J, Puhr R, Petoumenos K, Cooper DA, Woolley I, Gunathilake M, Raymond N, Varma R, O'Connor CC, Gracey DM.
Nephrology (Carlton). 2017 Jul 13. doi: 10.1111/nep.13100. [Epub ahead of print]

Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group.
HIV Med. 2017 Jul 13. doi: 10.1111/hiv.12532. [Epub ahead of print]

Physician testing for HIV in patients treated with tenofovir disoproxil fumarate and lamivudine monotherapy for hepatitis B virus.
Lau JSY, Ratnam D, Woolley I.
Sex Health. 2017 Jul 13. doi: 10.1071/SH17045. [Epub ahead of print]

Cryptococcal/CSF ventricular levels on MRI Brain in a man with AIDS.
Woolley I, Bhatt S, Anderson D.
Radiology of Infectious Diseases (2017), doi: 10.1016/j.jrid.2017.04.003.

High Rates of potentially infectious exposures between immunocompromised patients and their companion animals: An unmet need for education.
Gurry G, Campion V, Premawardena C, Woolley I, Shortt, Bowden DK, Kaplan Z, Dendle C.
Intern Med J. 2017 Mar;47(3):333-335. doi: 10.1111/imj.13361.

Integrase-resistant HIV in an antiretroviral-naive patient in Australia.
Rafiei N, Woolley I, Korman TM, Chibo D, Gooey M, McMahon JH.
AIDS. 2017 Feb 20;31(4):598-600. doi: 10.1097/QAD.0000000000001377. No abstract available.

Cryptococcemia in primary HIV infection.
Yeung VA, Azzam R, Dendle C, Graham M, Woolley IJ, Korman TM.
Int J STD AIDS. 2016 Feb 10. pii: 0956462416632139. [Epub ahead of print]

Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men.
Price J, Hoy J, Ridley E, Nyulasi I, Paul E, Woolley I.
Sex Health. 2015 Jun;12(3):240-8. doi: 10.1071/SH14084.

Isn't it time to talk about antiretroviral stewardship?
Woolley I.
J Chemother. 2016 Aug;28(4):352-4. doi: 10.1179/1973947815Y.0000000007. No abstract available.

Treatment durability and virological response in treatment-experienced HIV-positive patients receiving an integrase inhibitor based regimen: an Australian cohort study.
De La Mata NL, Cooper DA, Russell D, Smith D, Woolley I, O'Sullivan M, Wright S, Law M.
Sex Health. 2016; 13(4) 335-344 http://dx.doi.org/10.1071/SH15210

Maraviroc, as a switch option, in HIV-1 infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first N(t)RTI+PI/r regimen. Week 48 results of the randomised, multicentre MARaviroc switCH study (MARCH).
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Sierra Madero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group.
Clin Infect Dis. 2016 Jul 1;63(1):122-32. doi: 10.1093/cid/ciw207.

Treatment and disease outcomes of migrants from low- and middle-income countries in the Australian HIV Observational Database cohort.
Tilley DM, Griggs E, Hoy J, Wright ST, Woolley I, Burke M, O'Connor CC; Australian HIV Observational Database (AHOD).
AIDS Care. 2015 Nov;27(11):1410-7. doi: 10.1080/09540121.2015.1113227.

Tenofovir therapy for Hepatitis B may be commonly prescribed without HIV testing.
Deshpande S, Ko T, Roberts E, Lau JS, Horne K, Williams J, Kiss C, Ratnam D, Woolley I.J Acquir Immune Defic Syndr. 2015 Oct 20. [Epub ahead of print] No abstract available.

A history of infection with varicella is strongly predictive of the presence of varicella-zoster virus antibodies in a heterogenous Australian HIV cohort.
Gurry GA, Dendle C, Korman TM, Giles ML, Williams JH, Woolley IJ.
AIDS. 2015 Sep 24;29(15):2062-2064. No abstract available.

Acute HIV infection presenting as erythema multiforme in a 45-year-old heterosexual man.
Woolley IJ, Korman TM.
Med J Aust. 2015 Aug 3;203(3):137. No abstract available.

Clinic Network Collaboration and Patient Tracing to Maximize Retention in HIV Care.
McMahon JH, Moore R, Eu B, Tee BK, Chen M, El-Hayek C, Street A, Woolley I, Buggie A, Collins D, Medland N, Hoy J; Victorian Initiative for Patient Engagement and Retention (VIPER) study group.
PLoS One. 2015 May 26;10(5):e0127726. doi: 10.1371/journal.pone.0127726. eCollection 2015.

Factors associated with discussion of sexual activity and contraception in women with HIV.
Stewart ZA, Shipley K, Spelman T, Giles ML.
J Fam Plann Reprod Health Care. 2015 Apr 21. pii: jfprhc-2014-100937. doi: 10.1136/jfprhc-2014-100937. [Epub ahead of print]

Reducing viral load measurements to once a year in patients on stable, virologically suppressive cART regimen: findings from the Australian HIV Observational Database.
Rafiee M, Kariminia A, Wright S, Mills G, Woolley I, Smith D, Templeton JD, Law MG, Petoumenos K; Australian HIV Observational Database.
J AIDS Clin Res  2014 Dec;5(12). pii: 383.

Temporal trends of time to antiretroviral treatment initiation, interruption and modification: examination of patients diagnosed with advanced HIV in Australia.
Wright ST, Law MG, Cooper DA, Keen P, McDonald A, Middleton M, Woolley I, Kelly M, Petoumenos K; Australian HIV Observational Database.
Int J AIDS Soc 2015 Apr 10;18(1):19463. doi: 10.7448/IAS.18.1.19463. eCollection 2015.

Isn't it time to talk about antiretroviral stewardship?
Woolley I.
J Chemother. 2015 Mar 24:1973947815Y0000000007. [Epub ahead of print] No abstract available.

Latent infection in HIV-positive refugees and other immigrants in Australia.
Gurry GA, Dendle C, Woolley IJ.
Med J Aust. 2015 Mar 16;202(5):238-40.

Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men.
Price J, Hoy J, Ridley E, Nyulasi I, Paul E, Woolley I.
Sex Health 2015 Jun;12(3):240-8. doi: 10.1071/SH14084.

Mycobacterium haemophilum bone and joint infection in HIV/AIDS: case report and literature review.
Cross GB, Le Q, Webb B, Jenkin GA, Korman TM, Francis M, Woolley IJ.
Int J STD AIDS. 2015 Jan 10. pii: 0956462414565403. [Epub ahead of print]

C-reactive protein as a predictor of cardiovascular risk in HIV-infected individuals.
Westhorpe CL, Schneider HG, Dunne M, Middleton T, Sundararajan V, Spelman T, Carter V, Crowe SM, Dart T, Mijch A, Kotsanas D, Woolley I.
Sex Health 2014 Dec;11(6):580-2. doi: 10.1071/SH14130.

Macrophage MIF (Migration Inhibitory Factor): a potential biomarker for cardiovascular disease in persons with HIV?
Woolley IJ, Ayoub S, Crowe SM, Westhorpe C, Cherry CL, Visvanathan K, Morand E.
AIDS. 2014 Jul 17;28(11):1693-4. doi: 10.1097/QAD.0000000000000276. No abstract available.

Recent trends in response to combination antiretroviral therapy in Australia.
McManus H, Hoy JF, Woolley I, Boyd MA, Kelly MD, Mulhall B, Roth NJ, Petoumenos K, Law MG; the Australian HIV Observational Database.
Antivir Ther. 2014 Apr 4. doi: 10.3851/IMP2774. [Epub ahead of print]

The significance of HIV 'blips' in resource-limited settings: is it the same? Analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD).
Kanapathipillai R, McManus H, Kamarulzaman A, Lim PL, Templeton DJ, Law M, Woolley I.
PLoS One. 2014 Feb 7;9(2):e86122. doi: 10.1371/journal.pone.0086122. eCollection 2014.

Determinants of Viraemia Copy-Years in People with HIV/AIDS Following Initiation of Antiretroviral Therapy.
Wright ST, Hoy J, Mulhall B, O'Connor CC, Petoumenos K, Read T, Smith D, Woolley I, Boyd MA; on behalf of the Australian HIV Observational Database.
J Acquir Immune Defic Syndr. 2014 May 1;66(1):55-64. doi: 10.1097/QAI.0000000000000125.

The significance of low-level viremia in diverse settings: Analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD).
Kanapathipillai R, McManus H, Giles ML, Ng OT, Cuoung DD, Nguyen K, Read T, Woolley I. 
HIV Med. 2014 Aug;15(7):406-16. doi: 10.1111/hiv.12124. Epub 2014 Jan 26.

Antiretroviral Treatment Interruption and Loss to Follow-up in Two HIV cohorts in Australia and Asia: Implications for ‘Test and Treat’ Prevention Strategy.
Guy R, Wand H, McManus H, Vonthanak S, Woolley I, Honda M, Read T, Sirisanthana T, Zhou J, Carr A. on behalf of AHOD and TAHOD.
AIDS Patient Care STDS. 2013 Dec;27(12):681-91. doi: 10.1089/apc.2012.0439.

The inside story. Physicians' views on digital ano-rectal examination for anal cancer screening of HIV positive men who have sex with men.
Ong JJ, Chen M, Temple-Smith M, Walker S, Hoy J, Woolley I, Grulich AE, Fairley CK. 
J Med Screen. 2013;20(4):188-91. doi: 10.1177/0969141313515463.

The two-edged sword: vasculitis associated with HIV and Hepatitis C coinfection.
Ojaimi S, Lin MW, Singh KP, Woolley I.
Int J STD AIDS 2013 Jul 25.

HIV Replication Alters the Composition of Extrinsic Pathway Coagulation Factors and Increases Thrombin Generation
Baker JV, Brummel-Ziedins K, Neuhaus J, Duprez D, Cummins N, Dalmau D, DeHovitz J, Lehman C, Sullivan A, Woolley I, Kuller L, Neaton JD, Tracy RP. for the INSIGHT SMART Study Team.
J Am Heart Assoc 2013 Jul 29;2(4):e000264. doi: 10.1161/JAHA.113.000264.

Human immunodeficiency virus and menopause.
Kanapathipillai R, Hickey M, Giles M.
Menopause. 2013 Mar 25. [Epub ahead of print]

Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD).
Petoumenos K, van Leuwen M , Vajdic C, Woolley I, Chuah J, Templeton DJ, Grulich A, Law M.
HIV Med. 2013 Feb;14(2):77-84. doi: 10.1111/j.1468-1293.2012.01038.x. Epub 2012 Aug 30.

Inhibition of telomerase activity by HIV Nucleos(t)ide Reverse Transcriptase Inhibitors: a potential factor contributing to HIV-associated accelerated ageing.
Leeansyah E, Cameron PU, Solomon A, Tennakoon S, Velayudham P, Gouillou M, Spelman T, Hearps A, Fairley C, Smit DV, Pierce AB, Armishaw J, Crowe SM, Cooper DA, Koelsch KK, Liu JP, Chuah J, Lewin SR.
J Infect Dis. 2013 Jan 9. [Epub ahead of print]

HIV and pregnancy - how to manage conflicting recommendations from evidence based guidelines.
Giles ML. 
AIDS 2013;27(6):857-862, doi: 10.1097/QAD.0b013e32835ce308  Epub 2012 Nov 28. No abstract available

A qualitative study of HIV serodiscordant patients accessing assisted reproductive treatment.
Peak SA, Nowoweiski SJ, Giles ML.
J Reprod Infant Psych 2012;30(4):413-422. DOI:10.1080/02646838.2012.733362

Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and australia.
Achhra AC, Amin J, Hoy J, Tanuma J, Sirisanthana T, Nolan D, Merati T, Giles M.
AIDS Res Treat. 2012;2012:246280. Epub 2012 May 14.

Visiting friends and relatives may be a risk for non-adherence for HIV-positive travellers.
Woolley I, Bialy C.
Int J STD AIDS. 2012 Nov;23(11):833-4. doi: 10.1258/ijsa.2012.012063.

Successful use of Eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia.
Quach H, Lee LY. Smith B. Korman T. Woolley IJ.
AIDS. 2012 Sep 24;26(15):1977-9. No abstract available.

Nonoccupational post-exposure prophylaxis source tracing: is it really feasible in Australia?
Pierce AB, Armishaw J, Price B, Wright EJ, Dax EM, Fairley CK, Hoy JF.
HIV Med. 2012 Aug;13(7):436-8. doi: 10.1111/j.1468-1293.2011.00986.x. Epub 2012 Jan 25.

Adherence to HIV treatment guidelines for comorbid disease assessment and initiation of antiretroviral therapy.
Bloch M, Hoy J, Cunningham N, Roth N, Bailey M, Pierce A, Watson J, Carr A.
J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):478-88.

New HIV diagnosis after occupational exposure screening: the importance of reporting needlestick injuries.
Upjohn L. Stuart RL.  Korman TM. Woolley IJ. 
Intern Med J. 2012 Feb;42(2):202-4. doi: 10.1111/j.1445-5994.2011.02616.x.

Non-occupational post-exposure prophylaxis in Victoria, Australia: responding to high rates of re-presentation and low rates of follow-up.
Armishaw J, Hoy JF, Watson KM, Wright EJ, Price BG, Pierce AB.
Int J STD AIDS. 2011 Dec;22(12):714-8.

Comment on: The DART Trial: 'The Doctor's Dilemma' revisited.
Woolley I, Kanapathipillai R.
J Antimicrob Chemother. 2011 Sep;66(9):2192-3. Epub 2011 Jun 27.

Rat Bite Fever as the presenting illness in a patient with AIDS. 
Chean R, Stefanski DA, Woolley IJ, Francis MJ, Korman TM.
Infection. 2011 Jun;40(3):319-21. doi: 10.1007/s15010-011-0181-x. Epub 2011 Aug 30.

HIV seroconversions among male non-occupational post-exposure prophylaxis service users: a data linkage study.
Pierce AB, Yohannes K, Guy R, Watson KM, Armishaw J, Price B, Hoy JF, Wright EJ, Stoové MA.
Sex Health. 2011 Jun;8(2):179-83.

Triple class experience after initiation of combination antiretroviral treatment in Australia: survival and projections.
Pour SM, Woolley I, Canavan P, Chuah J, Russell DB, Law M, Petoumenos, K.
Sex Health. 2011:8(3):295-303.

CD4 Cell Responses to Combination Antiretroviral Therapy in Patients Starting Therapy at High CD4 Cell Counts.
Wright ST, Carr A, Woolley I, Giles M, Hoy J, Cooper DA, Lawma MG; on behalf of the Australian HIV Observational Database..
J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):72-9.

Outcomes from the first assisted reproduction program for HIV-serodiscordant couples in Australia.
Giles ML, Barak S, Baker G, Perna S, Tabrizi S, Greengrass V, Bourne H, Clarke GN, Peak SA, Hoy JF, Foster P, Knight RL, On Behalf Of The CVI Study Group.
Med J Aust. 2011 Nov 21;195(10):599-601.

Predictors and outcomes of HIV-infected antiretroviral-naive patients with discordant responses to combination antiretroviral treatment in Asian and Australian populations: results from APHOD.
Choi JY, Zhou J, Giles M, Broom J, Templeton DJ, Law MG, Chaiwarith R, Tanuma J; Asia-Pacific HIV Observational Database.
J Acquir Immune Defic Syndr. 2011 May 1;57(1):e13-5. No abstract available.

Low CD4 Count is Associated with an Increased Risk of Fragility Fracture in HIV-infected Patients.
Yong MK, Elliott JH, Woolley IJ, Hoy JF.
J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):205-10.

The Clinical Significance of CD4 Counts in Asian and Caucasian HIV-Infected Populations: Results from TAHOD and AHOD.
Achhra AC, Zhou J, Choi JY, Hoy J, Zhang F, Templeton DJ, Merati T, Woolley I, Petoumenos K, Amin J.
J Int Assoc Physicians AIDS Care (Chic). 2011 May-Jun;10(3):160-70. Epub 2011 Apr 20.

Trends in detectable viral load by calendar year in the Australian HIV Observational Database.
Law MG, Woolley I, Templeton DJ, Roth N, Chuah J, Mulhall B, Canavan P, McManus H, Cooper DA, Petoumenos K, Database TA.
J Int AIDS Soc. 2011 Feb 23;14(1):10.

N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients.
Duprez DA, Neuhaus J, Tracy R, Kuller LH, Deeks SG, Orkin C, Stoehr A, Woolley IJ, Neaton JD; for the INSIGHT SMART Group.
AIDS. 2011 Mar 13;25(5):651-7.

The Influence of Splenectomy on the Infectious Complications and Outcomes of people With HIV: Marked, Sustained Elevation in Risk of Severe Infection With Bacteria Including Streptococcus pneumoniae.
Polizzotto MN, Jones P, Cameron PU, Spelman D, Woolley IJ.
J Acquir Immune Defic Syndr. 2010 Nov 1;55(3):e24-e26. No abstract available.

Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial.
Martin A, Amin J, Cooper DA, Carr A, Kelleher AD, Bloch M, Baker D, Woolley I, Emery S; on behalf of the STEAL study group.
AIDS. 2010 Nov 13;24(17):2657-63.

Autoimmune haemolytic anaemia: an unusual presentation of HIV seroconversion disease.
Sherry NL, Woolley IJ, Korman TM.
AIDS. 2010 Jul 31;24(12):1968-70. No abstract available.

The "work" of women when considering and using interventions to reduce mother-to-child transmission (MTCT) of HIV.
Giles ML, Hellard ME, Lewin SR, O'Brien ML.
AIDS Care. 2009 Oct;21(10):1230-7.

Cost-effectiveness of HIV nonoccupational post-exposure prophylaxis in Australia.
Guinot D, Ho MT, Poynten IM, McAllister J, Pierce A, Pell C, Grulich AE.
HIV Med. 2009 Apr;10(4):199-208. Epub 2009 Jan 22.

Perinatal exposure to HIV among children born in Australia, 1982-2006.
McDonald AM, Zurynski YA, Wand HC, Giles ML, Elliott EJ, Ziegler JB, Kaldor JM.
Med J Aust. 2009 Apr 20;190(8):416-20.

Antenatal screening practice for infectious diseases by general practitioners in Australia.
Giles ML, Pedrana A, Jones C, Garland S, Hellard M, Lewin SR.
Aust N Z J Obstet Gynaecol. 2009 Feb;49(1):39-44.

HIV and pregnancy: screening and management update.
Giles M.
Curr Opin Obstet Gynecol. 2009 Apr;21(2):131-5. Review.

African Australians living with HIV: a case series from Victoria.
Lemoh CN, Baho S, Grierson J, Hellard M, Street A, Biggs BA.
Sex Health. 2010 Jun;7(2):142-8.

Delayed diagnosis of HIV infection in Victoria 1994 to 2006.
Lemoh C, Guy R, Yohannes K, Lewis J, Street A, Biggs B, Hellard M.
Sex Health. 2009 Jun;6(2):117-22.

Sudanese women living in Victoria, Australia: health-information-seeking behaviours and the availability, effectiveness and appropriateness of HIV/AIDS information
Palmer R, Lemoh C, Tham R, Hakim S, Biggs BA.
Diversity Health Social Care. 2009;6(2):109-20.

Working with West African migrant communities on HIV prevention in Australia.
Lemoh C, Biggs BA, Hellard M.
Sex Health. 2008 Dec;5(4):313-4. No abstract available.

Unrecognised vitamin D deficiency: low concentrations in African migrants with HIV in Australia.
Woolley IJ, Giles ML, Howard JE, Korman TM.
Sex Health. 2008 Dec;5(4):375-6. No abstract available.

HIV transmission: the ongoing importance of antenatal screening.
Upjohn LM, Korman TM, Giles ML.
N Z Med J. 2008 Sep 5;121(1281):94-5. No abstract available.

HIV infection and high density lipoprotein metabolism.
Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A, Sviridov D.
Atherosclerosis. 2008 Jul;199(1):79-86. Epub 2007 Dec 4.

Variable uptake of recommended interventions to reduce mother-to-child transmission of HIV in Australia, 1982-2005.
Giles ML, McDonald AM, Elliott EJ, Ziegler JB, Hellard ME, Lewin SR, Kaldor JM.
Med J Aust. 2008 Aug 4;189(3):151-4.

What are the barriers to offering HIV testing in an antenatal setting? A national study of obstetricians.
Giles ML, Garland SM, Lewin SR, Hellard ME.
AIDS. 2007 Jul 31;21(12):1601-6.

Cambodian-born individuals diagnosed with HIV in Victoria: epidemiological findings and health service implications.
Ayton DR, Guy RJ, Woolley IJ, Hellard ME.
Sex Health. 2007 Sep;4(3):209. No abstract available.

Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006.
Smyth K, Affandi JS, McArthur JC, Bowtell-Harris C, Mijch AM, Watson K, Costello K, Woolley IJ, Price P, Wesselingh SL, Cherry CL.
HIV Med. 2007 Sep;8(6):367-73.

Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART.
Rodriguez B, Valdez H, Mijch A, Watson K, Lederman MM, McComsey GA, Loupa CV, Woolley I.
J Int Assoc Physicians AIDS Care (Chic Ill). 2007 Sep;6(3):198-202. Epub 2007 Jun 19.

Macrolide use and the risk of vascular disease in HIV-infected men in the Multicenter AIDS Cohort Study.
Woolley IJ, Li X, Jacobson LP, Palella FJ, Ostergaard L.
Sex Health. 2007 Jun;4(2):111-9.

Acute pancreatitis caused by tipranavir/ritonavir-induced hypertriglyceridaemia.
Chapman SJ, Woolley IJ, Visvanathan K, Korman TM.
AIDS. 2007 Feb 19;21(4):532-3. No abstract available.

Occupational exposures experienced by medical students during overseas electives.
Smith P, Drummond C, Woolley I.
Aust Infect Control. 2006;11(4): 123 - 133.

A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy.
Carter VM, Woolley I, Jolley D, Nyulasi I, Mijch A, Dart A.
Sex Health. 2006 Dec;3(4):287-90.

Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.
Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J.
Intern Med J. 2005 Jan;35(1):67-8. No abstract available.

Eosinophilic folliculitis: an example of 'immune reconstitution folliculitis'?
Moyle M, Woolley IJ, Thevarajan I, Korman TM.
AIDS. 2004 Nov 19;18(17):2350-2. No abstract available.

Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management.
McComsey GA, Huang JS, Woolley IJ, Young B, Sax PE, Gerber M, Swindells S, Bonilla H, Gopalakrishnan G.
J Int Assoc Physicians AIDS Care (Chic Ill). 2004 Jul-Sep;3(3):86-91.

Chlamydia pneumoniae in HIV-infected patients and controls assessed by a novel whole blood interferon-gamma assay, serology and PCR.
Woolley IJ, Larsen M, Jones S, Gahan ME, Jasenko I, Johnsen SP, Wesselingh S, Fuller A, Ostergaard L.
Clin Microbiol Infect. 2004 Sep;10(9):820-5.

Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient.
Woolley IJ, Veitch AJ, Harangozo CS, Moyle M, Korman TM.
AIDS. 2004 Sep 3;18(13):1857-8. No abstract available.

Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?
Lange CG, Woolley IJ, Brodt RH.
Drugs. 2004;64(7):679-92. Review.

Anterior neck fat deposition in lipodystrophy syndrome; a new variant on a theme?
Woolley IJ, Mijch AM, Carter VM, Archer B, Hoy JF.
AIDS. 2003 Aug 15;17(12):1857-8. No abstract available.

Sequential cutaneous drug reactions to protease inhibitors in the context of occupational post-exposure prophylaxis.
Woolley I, Tapley N, Korman TM.
AIDS. 2003 Jul 25;17(11):1709. No abstract available.